InVivo Therapeutics shared its first quarter 2018 financial results.
Here are five details.
1. In the first quarter, InVivo experiences a net loss of $4.8 million compared to a $6.4 million net loss in the same period in 2017.
2. Decreases in operating expenses allowed for a smaller net loss. The company reported $2 million in research and development expenses in the first quarter of 2018.
3. At the end of the quarter, InVivo had $11.6 million in cash and cash equivalents on hand.
4. During the first quarter, InVivo named Richard Toselli, MD, its president and CEO. He is a board-certified neurosurgeon.
5. InVivo also entered into a common stock purchase agreement with Lincoln Park Capital Fun to sell up to $15 million in shares of common stock to Lincoln Park.